The functional assessment of cancer therapy-prostate (FACT-P) scales in men 45-55 years of age with prostate cancer

2019 ◽  
Vol 18 (3) ◽  
pp. e2449
Author(s):  
S. Semenov ◽  
S. Krasny
Urology ◽  
1997 ◽  
Vol 50 (6) ◽  
pp. 920-928 ◽  
Author(s):  
Peg Esper ◽  
Fei Mo ◽  
Gerald Chodak ◽  
Michael Sinner ◽  
David Cella ◽  
...  

2015 ◽  
Vol 24 (10) ◽  
pp. 2397-2402 ◽  
Author(s):  
Carlos K. H. Wong ◽  
Edmond P. H. Choi ◽  
James H. L. Tsu ◽  
Brian S. H. Ho ◽  
Ada T. L. Ng ◽  
...  

Author(s):  
Dharam Kaushik ◽  
Pankil K. Shah ◽  
Neelam Mukherjee ◽  
Niannian Ji ◽  
Furkan Dursun ◽  
...  

Abstract Background Diagnosis and treatment of prostate cancer is associated with anxiety, fear, and depression in up to one-third of men. Yoga improves health-related quality of life (QoL) in patients with several types of cancer, but evidence of its efficacy in enhancing QoL is lacking in prostate cancer. Methods In this randomized controlled study, 29 men newly diagnosed with localized prostate cancer were randomized to yoga for 6 weeks (n = 14) or standard-of-care (n = 15) before radical prostatectomy. The primary outcome was self-reported QoL, assessed by the Expanded Prostate Index Composite (EPIC), Functional Assessment of Cancer Therapy-Prostate (FACT-P), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT–F), Functional Assessment of Cancer Therapy-General (FACT-G) at baseline, preoperatively, and 6 weeks postoperatively. Secondary outcomes were changes in immune cell status and cytokine levels with yoga. Results The greatest benefit of yoga on QoL was seen in EPIC-sexual (mean difference, 8.5 points), FACIT-F (6.3 points), FACT-Functional wellbeing (8.6 points), FACT-physical wellbeing (5.5 points), and FACT-Social wellbeing (14.6 points). The yoga group showed increased numbers of circulating CD4+ and CD8+ T-cells, more production of interferon-gamma by natural killer cells, and increased Fc receptor III expression in natural killer cells. The yoga group also showed decreased numbers of regulatory T-cells, myeloid-derived suppressor cells, indicating antitumor activity, and reduction in inflammatory cytokine levels (granulocyte colony-stimulating factor [0.55 (0.05–1.05), p = 0.03], monocyte chemoattractant protein [0.22 (0.01–0.43), p = 0.04], and FMS-like tyrosine kinase-3 ligand [0.91 (−0.01, 1.82), p = 0.053]. Conclusions Perioperative yoga exercise improved QoL, promoted an immune response, and attenuated inflammation in men with prostate cancer. Yoga is feasible in this setting and has benefits that require further investigation. Trial registration clinicaltrials.org (NCT02620033).


2009 ◽  
Vol 16 (5) ◽  
pp. 522-525 ◽  
Author(s):  
Tetsuya Fujimura ◽  
Satoru Takahashi ◽  
Haruki Kume ◽  
Takumi Takeuchi ◽  
Tadaichi Kitamura ◽  
...  

Author(s):  
Priscila Antonichelli de Held ◽  
Wagner Eduardo Matheus ◽  
Angela Maria Elizabeth Piccolotto Naccarato ◽  
Roberta Cunha Matheus Rodrigues ◽  
Aline Akel Ferruccio ◽  
...  

2015 ◽  
Vol 33 (19) ◽  
pp. 2151-2157 ◽  
Author(s):  
Michael Brundage ◽  
Matthew R. Sydes ◽  
Wendy R. Parulekar ◽  
Padraig Warde ◽  
Richard Cowan ◽  
...  

Purpose The NCIC CTG PR3/MRC PR07 randomized phase III trial compared androgen-deprivation therapy (ADT) alone versus ADT with radiotherapy (RT) for patients with locally advanced prostate cancer. This article reports the health-related quality-of-life (HRQOL) outcomes of this trial. Patients and Methods A total of 1,205 patients were randomly allocated to either ADT alone or ADT with RT. HRQOL was assessed at baseline and every 6 months thereafter using the European Organisation for Research and Treatment of Cancer Core Questionnaire and a prostate cancer–specific checklist or the Functional Assessment of Cancer Therapy–Prostate questionnaire. Mean changes from baseline scores for five function domains and nine symptom domains were analyzed as those most relevant to ADT and RT. The proportions of patients with improved, stable, or worsened HRQOL scores according to instrument-specific minimal important differences were calculated. Results Baseline questionnaires were completed by 1,028 patients (88%). At 6 months, RT had a statistically significant impact on mean score for bowel symptoms (P = .02), diarrhea (P < .001), urinary function (P = .003), and erectile dysfunction (P = .008); by 3 years, however, there were no significant between-group differences in any domain. Generalized linear mixed modeling revealed no significant between-arm differences in any of the function scales but showed significant deterioration in both arms over time for Functional Assessment of Cancer Therapy–Prostate total score, treatment outcome index, and physical and functional well-being. Conclusion The addition of RT to ADT for patients with locally advanced prostate cancer significantly improved overall survival and had only modest and transient negative impact on relevant domains of HRQOL.


Sign in / Sign up

Export Citation Format

Share Document